The vaccination campaign against COVID-19 in Brazil started on January 2021. Over two years later, around 88 percent of the country's population had received at least one dose of a vaccine against the disease. As of that date, approximately 81.8 percent of Brazilians were fully vaccinated with the recommended amount of doses for immunization. Brazil ranked fifth among Latin American countries with the largest number of COVID-19 vaccination doses per 100 population.

Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

View daily updates and historical trends for Brazil Coronavirus Vaccination Rate: Any Dosage. Source: Our World in Data. Track economic data with YCharts …

Forecast: Measles Vaccination Rates Among Children in Brazil 2022 - 2026 Discover more data with ReportLinker!

The number of COVID-19 vaccination doses administered per 100 people in Brazil rose to 226 as of Oct 27 2023. This dataset includes a chart with historical data for Brazil Coronavirus Vaccination Rate.

Forecast: Diphtheria, Tetanus and Pertussis Vaccination Rates Among Children in Brazil 2022 - 2026 Discover more data with ReportLinker!

As of August 13, 2024 most Latin American and Caribbean countries had started the COVID-19 vaccination process. While Brazil had administered around 486 million doses of the vaccine, Mexico had applied approximately 223 million doses. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Time series data for the statistic Immunization, measles (% of children ages 12-23 months) and country Brazil. Indicator Definition:Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.The indicator "Immunization, measles (% of children ages 12-23 months)" stands at 93.00 as of 12/31/2024, the highest value since 12/31/2017. Regarding the One-Year-Change of the series, the current value constitutes an increase of 6.90 percent compared to the value the year prior.The 1 year change in percent is 6.90.The 3 year change in percent is 27.40.The 5 year change in percent is 2.20.The 10 year change in percent is -4.12.The Serie's long term average value is 86.24. It's latest available value, on 12/31/2024, is 7.83 percent higher, compared to it's long term average value.The Serie's change in percent from it's minimum value, on 12/31/1980, to it's latest available value, on 12/31/2024, is +63.16%.The Serie's change in percent from it's maximum value, on 12/31/1997, to it's latest available value, on 12/31/2024, is -6.06%.

Brazil BR: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 81.000 % in 2022. This records an increase from the previous number of 73.000 % for 2021. Brazil BR: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 91.000 % from Dec 1980 (Median) to 2022, with 43 observations. The data reached an all-time high of 99.000 % in 2012 and a record low of 57.000 % in 1980. Brazil BR: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Brazil – Table BR.World Bank.WDI: Social: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.;WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).;Weighted average;

The Brazil vaccine market was valued at USD 3.92 Billion in 2024, driven by the surge in infectious disease cases and rising public-private partnerships in the region. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 7.09 Billion by 2034. The market is propelled by the growing public health infrastructure and high vaccination acceptance rates. Expanding adult vaccination programs and advancements in mRNA vaccine technologies are expected to fuel demand in the forecast period.

Percentage of municipalities according to vaccination coverage classification, Minas Gerais, Brazil, 2018 to 2022.

COVID-19 was first detected in Brazil on March 1, 2020, making it the first Latin American country to report a case of the novel coronavirus. Since then, the number of infections has risen drastically, reaching approximately 38 million cases by May 11, 2025. Meanwhile, the first local death due to the disease was reported in March 19, 2020. Four years later, the number of fatal cases had surpassed 700,000. The highest COVID-19 death toll in Latin America With a population of more than 211 million inhabitants as of 2023, Brazil is the most populated country in Latin America. This nation is also among the most affected by COVID-19 in number of deaths, not only within the Latin American region, but also worldwide, just behind the United States. These figures have raised a debate on how the Brazilian government has dealt with the pandemic. In fact, according to a study carried out in May 2021, more than half of Brazilians surveyed disapproved of the way in which former president Jair Bolsonaro had been dealing with the health crisis. In comparison, a third of respondents had a similar opinion about the Ministry of Health. Brazil’s COVID-19 vaccination campaign rollout Brazil’s vaccination campaign started at the beginning of 2021, when a nurse from São Paulo became the first person in the country to get vaccinated against the disease. A few years later, roughly 88 percent of the Brazilian population had received at least one vaccine dose, while around 81 percent had already completed the basic immunization scheme. With more than 485.2 million vaccines administered as of March 2023, Brazil was the fourth country with the most administered doses of the COVID-19 vaccine globally, after China, India, and the United States.Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Actual value and historical data chart for Brazil Immunization Bcg Percent Of One Year Old Children

Mean annual change, as percentages, in MMR first dose vaccine coverage by region in Brazil, from multilevel mixed effects linear regressions, adjusted for year with state-specific random effects (5565 municipalities within 27 states).

ABSTRACT: Introduction: In 2014, Brazil introduced a universal immunization program against the hepatitis A virus (HAV) for children in the second year of life, using a single dose of inactivated virus vaccine. The objective of this study was to evaluate the vaccination coverage (VC) against HAV in Brazil, against the incidence of cases reported five years after the implementation of the program. Methodology: Secondary data were obtained by searching free access electronic sites of the Ministry of Health, Department of Informatics of the Unified Health System (Departamento de Informática do Sistema Único de Saúde - DATASUS), for incidence analysis and VC from 2014 to 2018. Results: VC ranged from 60.13 to 97.07%. The homogeneity of VC against hepatitis A did not reach the established goal throughout all states but for a few exceptions. After 2015, CV decreased in all regions of the country. Despite insufficient coverage, a concomitant reduction in the incidence of Hepatitis A took place throughout the country. The incidence rate fell from 3.29 to 0.80/100,000 between 2014 and 2018. However, there was an interruption in the pace of incidence fall between 2017 and 2018, which may be a consequence of insufficient VC. This phenomenon seems to be part of a widespread downward trend in vaccination effort across the country, also verified for other vaccines, such as poliomyelitis and measles, mumps and rubella vaccine. Conclusion: These figures suggest the need for implementing efforts to improve hepatitis A VC rates in the country.

As of May 2021, more than nine out of ten Brazilians were either already vaccinated or planning to get vaccinated against COVID-19, according to a survey conducted in the country. Meanwhile, eight percent of people surveyed were not planning to get vaccinated.

Actual value and historical data chart for Brazil Immunization Measles Percent Of Children Ages 12 23 Months

Actual value and historical data chart for Brazil Immunization Hepb3 Percent Of One Year Old Children

Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

Invasive meningococcal disease is a life-threatening infection preventable through vaccination. Pediatric vaccination rates have declined during the coronavirus disease 2019 (COVID-19) pandemic. This survey aimed to understand how parents’ attitudes and behaviors have changed during the pandemic with regard to immunization and, more specifically, meningococcal vaccination. An online survey was emailed to parents of eligible children 0–4 years, following the selection process from UK, France, Germany, Italy, Brazil, Argentina, and Australia; and of adolescents 11–18 years from US. Data collection took place 19 January–16 February 2021. Quotas were set to ensure a representative sample. Eleven questions relating to general perceptions around vaccination and attitudes and behaviors toward meningitis vaccination were displayed. On 4,962 parents (average 35 years) participating in the survey, most (83%) believed important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Nearly half of routine vaccine appointments were delayed or canceled due to the pandemic, and 61% of respondents were likely to have their children catch up once COVID-19 restrictions were lifted. 30% of meningitidis vaccination appointments were canceled or delayed during the pandemic, and 21% of parents did not intend to reschedule them because of lockdown/stay at home regulations, and fear of catching COVID-19 in public places. It is crucial to communicate clear instructions to health workers and the general population and to provide appropriate safety precautions in vaccination centers. This will help to maintain vaccination rates and limit infections to prevent future outbreaks. What is the context?Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death.Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis.Vaccination rates have declined during the coronavirus (COVID-19) pandemic. Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death. Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis. Vaccination rates have declined during the coronavirus (COVID-19) pandemic. What is new?We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic.Results were reviewed by health care professional experts as well as by patient authors (IMD survivors).Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic.Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19.Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic. Results were reviewed by health care professional experts as well as by patient authors (IMD survivors). Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19. Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. What is the impact?It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken.Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic. It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken. Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic.